Home Agenda Call for Abstracts Sponsors & Exhibitors PARTNERS Registration Venue FAQ How it works

AGENDA PRE-PROGRAMME

📅 Day 1 – November 12, 2026

08:30 – 09:20

Registration & Welcome Coffee

09:20 – 09:30

Welcome Address – Prof. A. Bennaceur Griscelli

Session I – iPSC and Cancer Therapy & Models

09:30 – 10:15

Keynote Conference: IPSC-based NK-Cell Therapies in Cancer

Dan Kaufman, UCSD, San Diego, USA

10:20 – 11:10

Cancer iPSC Models & Drug Development

10:20 – 10:45

iPSC-based Cancer Organoid Models

Ali Turhan, Inserm, University Paris Saclay, France

10:45 – 11:10

New paradogm for iPSC-based Cancer Vaccines

Frank Griscelli, Inserm, University Paris Saclay, France

11:10 – 11:30 Coffee Break

11:30 – 12:30

Early Clinical Developments

11:30 – 11:50

Clinical-Grade iPS Cell Stock: A Decade of Progress, Current Status, and Future Challenges

Naosuke Nakamura, CiRA Foundation, Japan

11:50 – 12:10

Mechanistic Analysis and Drug Discovery in Neurodegenerative Diseases Using Patient-Derived Stem Cells

Haruhisa Inoue, CiRA Foundation, Japan

12:10 – 12:30

4 Short talks in Cancer

12:30 – 14:00 Lunch & Sponsor Booth Visits

Session II – iPSCs and Regenerative Medicine

14:00 – 14:45

Keynote Conference: Clinical Trials using Heart Patches derived from iPSC

Keiichi Fukuda, HeartSeed, Japan

14:45 – 15:30

Keynote Conference: Mini-Heart Tech Platform in Cardiology

Ronald Li, NovoHeart, Hong Kong

15:30 – 15:45

Key considerations for the development of hPSC-based cell therapies

Jung Hyun Kim, Ajou University, South Korea

15:45 – 16:00

Clinical Translation of an iPSC-Derived 3D Chondrospheroid Therapy for Osteoarthritis: First-in-Human Experience with MIUChon™

Hyeon Jin Ju, Ajou University, South Korea

16:00 – 16:30 Coffee Break & Poster Session

16:30 – 17:30

iPSC-Based Therapies in Neurology & Ophthalmology

16:30 – 16:50

iPSC-derived Huntington Therapies

Jihwan Song, CHA Stem Cell Institute Seoul, South Korea

16:50 – 17:10

iPSC-based Huntington Models

Anselme Perrier, Inserm CEA, France

17:10 – 17:30

Pluripotent Stem Cell-Based Retinal Cell Therapies

Christelle Monville, University Evry, I-STEM, France

17:30 – 18:10

iPSC-Derived Preclinical Research

Short Talks

End of Day 1

📅 Day 2 – November 13, 2026

Session III – Novel Approaches in iPSC Manufacturing and Differentiation

09:00 – 09:45

Keynote Conference: Driving iPSC Fate Through Direct Nuclear Reprogramming

Alex Ng, GC Therapeutics, USA

09:45 - 10:05

Safety, Consistency & Manufacturing

09:45 – 10:05

Induced Pluripotent Stem Cells: Mapping the drug pipeline landscape and trends

MabDesign, France

10:05 – 10:25

Manufacturing iPSC-Derived NK Cells

Boris Greber, Catalent, Germany

10:25 – 10:45

ESC-based MSC manufacturing in clinical trials

Yu Alex Zhang, Zephyrim Biotechnologies, Beijing, China

10:45 – 11:00 Coffee Break

11:00 – 11:45

European cGMP iPSC Landscape

HaploiPSC Program in Europe

Anna Veiga, Institut d'Investigació Biomèdica de Bellvitge. IDIBELL, Spain

International Quality Control Round Assessment

Anna Falk, University of Lund, Sweden

Comprehensive Genomic-landscape of cGMP iPSC and engineered cells

Annelise Bennaceur Griscelli, CiTHERA, France

11:45 – 12:30

Keynote Conference: Reverse Genetic Engineering Stem Cell Sources for Safe and Optimized Universal Therapy

Andras Nagy, University of Toronto, Canada

12:30 – 14:00 Lunch & Sponsor Booth Visits

Session IV – Novel iPSC-Derived Cell Therapy Products & Technologies

14:00 – 14:45

Keynote Conference: Chemical Reprogramming and ciPSC-Derived Islets for Diabetes Therapy

Hongkui Deng, Beijing University, China

14:45 – 15:15

Novel ESC based therapeutics for sensorial hearing loss

Marcelo Rivolta, University of Sheffield, UK

15:15 – 16:00

Panel Discussion : Allogeneic versus Autologous iPSCs in clinical applications

Chairman : Glyn Stacey, with H. Deng, G. Shumann, A. Kurtz, A. Nagy, A Bennaceur, A Turhan, A Veiga

16:00 – 16:15 Coffee Break

16:15 – 17:15

iPSC Technology: Differentiation, Maturation and Beyond

Short talks

17:15 Closing Remarks

SCIENTIFIC ADVISORY BOARD

The Agenda has been setup by the Scientific Advisory Board composed of the following Experts :

Prof. Annelise Bennaceur Griscelli

Professor Hematology at
Paris Saclay University,
Director of CiTHERA, the Center for iPS Cell Therapies
Coordinator of The National iPSC Infrastructure INGESTEM,
Group Leader at INSERM U1310, France

Prof. Ali Turhan

Professor of Hematology
Paris Saclay University
Director of Clinical iPSC Program at CiTHERA, and National Pluripotent Stem Cell Infrastructure INGESTEM,
Group Leader at INSERM U1310, France

Prof. Anna Veiga

Director of the Barcelona Stem Cell Bank
Group leader at Pluripotent Stem Cell Therapy research group at the Regenerative Medicine Program (REGENBELL) at Institut d’ Investigació Biomèdica de Bellvitge (IDIBELL), Spain

Dr. Glyn Stacey

Professor at the Universities of Bedfordshire and Suffolk,UK
Institute of Stem Cell and Regeneration, CAS, Beijing, China

Dr. Anselme L. Perrier

Research Director at INSERM
Group leader at the CEA/CNRS U9199 Laboratory of Neurodegenerative Diseases,MIRCEN Infrastructure, France

Dr. Pierre Savatier

Research Director at INSERM
Stem-cell & Brain Research Institute (SBRI)
National Pluripotent Stem Cell Infrastructure INGESTEM, France

iPSCs : Recent Clinical Insights & Progress